144 related articles for article (PubMed ID: 26894886)
1. The Impact of Mast Cell Density on the Progression of Bone Disease in Multiple Myeloma Patients.
Vyzoukaki R; Tsirakis G; Pappa CA; Devetzoglou M; Tzardi M; Alexandrakis MG
Int Arch Allergy Immunol; 2015; 168(4):263-8. PubMed ID: 26894886
[TBL] [Abstract][Full Text] [Related]
2. Positive correlation between bone marrow mast cell density and ISS prognostic index in patients with multiple myeloma.
Pappa CA; Tsirakis G; Roussou P; Xekalou A; Goulidaki N; Konsolas I; Alexandrakis MG; Stathopoulos EN
Leuk Res; 2013 Dec; 37(12):1628-31. PubMed ID: 24183234
[TBL] [Abstract][Full Text] [Related]
3. High density of tryptase-positive mast cells in patients with multiple myeloma: correlation with parameters of disease activity.
Devetzoglou M; Vyzoukaki R; Kokonozaki M; Xekalou A; Pappa CA; Papadopoulou A; Alegakis A; Androulakis N; Alexandrakis MG
Tumour Biol; 2015 Nov; 36(11):8491-7. PubMed ID: 26026586
[TBL] [Abstract][Full Text] [Related]
4. Correlation of Mast Cell Density With Angiogenic Cytokines in Patients With Active Multiple Myeloma.
Vyzoukaki R; Tsirakis G; Pappa CA; Androulakis N; Kokonozaki M; Tzardi M; Alexandrakis MG
Clin Ther; 2016 Feb; 38(2):297-301. PubMed ID: 26740291
[TBL] [Abstract][Full Text] [Related]
5. Relationship between serum levels of vascular endothelial growth factor, hepatocyte growth factor and matrix metalloproteinase-9 with biochemical markers of bone disease in multiple myeloma.
Alexandrakis MG; Sfiridaki A; Miyakis S; Pappa C; Kandidaki E; Alegakis A; Margioris AN
Clin Chim Acta; 2007 Apr; 379(1-2):31-5. PubMed ID: 17234170
[TBL] [Abstract][Full Text] [Related]
6. Expression of receptor activator of nuclear factor kappaB ligand on bone marrow plasma cells correlates with osteolytic bone disease in patients with multiple myeloma.
Heider U; Langelotz C; Jakob C; Zavrski I; Fleissner C; Eucker J; Possinger K; Hofbauer LC; Sezer O
Clin Cancer Res; 2003 Apr; 9(4):1436-40. PubMed ID: 12684416
[TBL] [Abstract][Full Text] [Related]
7. Mast cells influence the proliferation rate of myeloma plasma cells.
Pappa CA; Tsirakis G; Stavroulaki E; Kokonozaki M; Xekalou A; Konsolas I; Alexandrakis MG
Cancer Invest; 2015 Apr; 33(4):137-41. PubMed ID: 25738408
[TBL] [Abstract][Full Text] [Related]
8. Bone marrow mast cell density correlates with serum levels of VEGF and CXC chemokines ENA-78 and GRO-α in multiple myeloma.
Pappa CA; Tsirakis G; Devetzoglou M; Zafeiri M; Vyzoukaki R; Androvitsanea A; Xekalou A; Sfiridaki K; Alexandrakis MG
Tumour Biol; 2014 Jun; 35(6):5647-51. PubMed ID: 24563338
[TBL] [Abstract][Full Text] [Related]
9. Selective inhibition of matrix metalloproteinase-2 in the multiple myeloma-bone microenvironment.
Shay G; Tauro M; Loiodice F; Tortorella P; Sullivan DM; Hazlehurst LA; Lynch CC
Oncotarget; 2017 Jun; 8(26):41827-41840. PubMed ID: 28611279
[TBL] [Abstract][Full Text] [Related]
10. Clinical, biological, and molecular characteristics of clonal mast cell disorders presenting with systemic mast cell activation symptoms.
Alvarez-Twose I; González de Olano D; Sánchez-Muñoz L; Matito A; Esteban-López MI; Vega A; Mateo MB; Alonso Díaz de Durana MD; de la Hoz B; Del Pozo Gil MD; Caballero T; Rosado A; Sánchez Matas I; Teodósio C; Jara-Acevedo M; Mollejo M; García-Montero A; Orfao A; Escribano L
J Allergy Clin Immunol; 2010 Jun; 125(6):1269-1278.e2. PubMed ID: 20434205
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of bone marrow angiogenesis in multiple myeloma: use of light microscopy as well as computerized image analyzer in the assessment of microvessel density and total vascular area in multiple myeloma and its correlation with various clinical, histological, and laboratory parameters.
Bhatti SS; Kumar L; Dinda AK; Dawar R
Am J Hematol; 2006 Sep; 81(9):649-56. PubMed ID: 16845660
[TBL] [Abstract][Full Text] [Related]
12. Angiogenic factors in multiple myeloma: higher levels in bone marrow than in peripheral blood.
Di Raimondo F; Azzaro MP; Palumbo G; Bagnato S; Giustolisi G; Floridia P; Sortino G; Giustolisi R
Haematologica; 2000 Aug; 85(8):800-5. PubMed ID: 10942925
[TBL] [Abstract][Full Text] [Related]
13. Upregulation of Syndecan-1 in the bone marrow microenvironment in multiple myeloma is associated with angiogenesis.
Andersen NF; Kristensen IB; Preiss BS; Christensen JH; Abildgaard N
Eur J Haematol; 2015 Sep; 95(3):211-7. PubMed ID: 25353275
[TBL] [Abstract][Full Text] [Related]
14. Serum levels of total-RANKL in multiple myeloma.
Jakob C; Goerke A; Terpos E; Sterz J; Heider U; Kühnhardt D; Ziefle S; Kleeberg L; Mieth M; Metzler Iv; Müller C; Sezer O
Clin Lymphoma Myeloma; 2009 Dec; 9(6):430-5. PubMed ID: 19951882
[TBL] [Abstract][Full Text] [Related]
15. Angiogenesis in multiple myeloma.
Vacca A; Ria R; Reale A; Ribatti D
Chem Immunol Allergy; 2014; 99():180-96. PubMed ID: 24217610
[TBL] [Abstract][Full Text] [Related]
16. Interleukin-10 Induces Both Plasma Cell Proliferation and Angiogenesis in Multiple Myeloma.
Alexandrakis MG; Goulidaki N; Pappa CA; Boula A; Psarakis F; Neonakis I; Tsirakis G
Pathol Oncol Res; 2015 Sep; 21(4):929-34. PubMed ID: 25743259
[TBL] [Abstract][Full Text] [Related]
17. Systemic levels of interleukin-6 and matrix metalloproteinase-9 in patients with multiple myeloma may be useful as prognostic indexes of bone disease.
Sfiridaki A; Miyakis S; Tsirakis G; Alegakis A; Passam AM; Kandidaki E; Margioris AN; Alexandrakis MG
Clin Chem Lab Med; 2005; 43(9):934-8. PubMed ID: 16176173
[TBL] [Abstract][Full Text] [Related]
18. Dysregulation of the receptor activator of NF-kappaB ligand and osteoprotegerin production influence the apoptosis of multiple myeloma patients' bone marrow stromal cells co-cultured with myeloma cells.
Zdzisińska B; Bojarska-Junak A; Walter-Croneck A; Kandefer-Szerszeń M
Arch Immunol Ther Exp (Warsz); 2010 Apr; 58(2):153-63. PubMed ID: 20157786
[TBL] [Abstract][Full Text] [Related]
19. A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer.
Body JJ; Facon T; Coleman RE; Lipton A; Geurs F; Fan M; Holloway D; Peterson MC; Bekker PJ
Clin Cancer Res; 2006 Feb; 12(4):1221-8. PubMed ID: 16489077
[TBL] [Abstract][Full Text] [Related]
20. Pentraxin 3 (PTX3) inhibits plasma cell/stromal cell cross-talk in the bone marrow of multiple myeloma patients.
Basile A; Moschetta M; Ditonno P; Ria R; Marech I; De Luisi A; Berardi S; Frassanito MA; Angelucci E; Derudas D; Specchia G; Curci P; Pavone V; Rossini B; Ribatti D; Bottazzi B; Mantovani A; Presta M; Dammacco F; Vacca A
J Pathol; 2013 Jan; 229(1):87-98. PubMed ID: 22847671
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
